9wgUTAOQ_edited.jpg

ABOUT US

Lindy Biosciences is addressing formulation challenges in biologics. The company’s technology produces spherical, dense, stable particles of a therapeutic protein, ideal for high-concentration suspensions. These high-dose suspensions combine stability with ease of delivery, enabling subcutaneous delivery, decreasing administration costs, increasing patient compliance, and enabling new high-dose therapies.

Leadership Team

Headshot 1.png

Deborah Bitterfield, PhD

Founder & CEO

A. Neil Jones
Headshot 1.png

Deborah Bitterfield, PhD

Founder & CEO

Deborah Bitterfield

Deborah has over 10 years of Pharma/Biotech industry, which reflects positions across a broad range of strategic and operational disciplines including biotherapeutics and medical devices. Prior to launching Lindy Biosciences in 2017, Deborah joined Southeast TechInventures, an innovation lab that partners with university inventors to further develop promising university technologies. Deborah began her career at Duke University in the Program on Values & Ethics in the Marketplace. She holds a PhD in Materials Science from Duke University with a focus in biomaterials.

Headshot 3.png

A. Neil Jones

VP, Corporate Strategic Partnerships

A. Neil Jones
Headshot 3.png

A. Neil Jones

VP, Corporate Strategic Partnerships

A. Neil Jones

Neil brings over 20 years’ experience in the pharmaceutical and biotech industry with a career that has spanned the continuum from bench top drug discovery to executive leadership in international business development and marketing strategies. As the Vice-President of Corporate Strategic Partnerships at Lindy, he is responsible for building their global drug formulation and delivery platform technology brand, fortifying its industry partnerships as well as navigating the company’s corporate growth strategy. Delivering an innovative technology for Patients suffering from chronic diseases.

Headshot 2.png

John Savage, PhD

Technology Advancement Director

John is responsible for managing daily research & development activities and partner relations at Lindy. His experience in the pharmaceutical industry encompasses product development in the fields of ophthalmology, inhaled, dermatology, and parenterals ranging from invention and early development through GMP manufacturing for multiple human clinical trials. Prior to joining Lindy Biosciences in 2019, John worked at Liquidia Technologies and Envisia Therapeutics. He received his PhD in Physics from the University of Massachusetts, Amherst.

John Savage

Board Members

Headshot 1.png

Deborah Bitterfield, PhD

Founder & CEO

Headshot 1.png

Deborah Bitterfield, PhD

Founder & CEO

Deborah has over 10 years of Pharma/Biotech industry, which reflects positions across a broad range of strategic and operational disciplines including biotherapeutics and medical devices. Prior to launching Lindy Biosciences in 2017, Deborah joined Southeast TechInventures, an innovation lab that partners with university inventors to further develop promising university technologies. Deborah began her career at Duke University in the Program on Values & Ethics in the Marketplace. She holds a PhD in Materials Science from Duke University with a focus in biomaterials. 

Deborah Bitterfield, PhD
Karen Lavert.jpg

Karen LeVert

Director

Karen LeVert is no stranger to the venture world with commercializing early stage technologies for the last 18 years. She has a long history of commercializing early stage technologies from university research labs and launching them into the marketplace. These commercialization efforts were realized via innovation labs she co-founded and led: Southeast TechInventures (STI) for medical technologies and Ag TechInventures (AgTI) for agriculture.

Karen LeVert
Karen Lavert.jpg

Karen LeVert

Director

Karen LeVert

Karen LeVert has a long history of commercializing early stage technologies from university research labs and launching them into the marketplace. These commercialization efforts were realized via innovation labs she co-founded and led: Southeast TechInventures (STI) for medical technologies and Ag TechInventures (AgTI) for agriculture. Ms. LeVert’s business experience encompasses both corporate and entrepreneurial worlds with over twenty-five years of successful leadership experience in executive management, start-ups, and technology commercialization. Ms. LeVert earned an MBA from the University of Dayton and an Information Technology undergraduate degree from Eastern Michigan University.

Omar%20Flores_edited.jpg

Omar Flores, PhD

Director

Omar%20Flores_edited.jpg

Dr. Flores has extensive experience in venture capital and startups. He has held leadership positions at Mountain Group Capital, Alumshares, NuSirt Biopharma, Phoenix FCR Biosciences and Vulcan Biosciences. Dr. Flores received his Ph.D. in Molecular Pharmacology from the University of Miami, completed a postdoctoral fellowship at Duke University as a Hoffman La-Roche fellow and completed an MBA from the University of North Carolina Kenan-Flagler Business School.

Omar Flores

Omar Flores, PhD

Director

sreekar.jpg

Sreekar Gadde

Director

sreekar.jpg

Sreekar Gadde

Director

Sreekar Gadde is the Executive Director for BlueTree Allied Angels, and leverages his background in engineering, law, and business to assist management teams in growing their company and, specifically, with developing an IP strategy that complements the company’s business strategy.  Sree’s work experience spans various fields including Artificial Intelligence, medicine, data analytics, and consumer goods. Sree also works with companies to identify what differentiates them from their competition and determine what forms of IP provide them the best strategic value in view of that differentiation. 

Sreekar Gadde